Fulgent Genetics, Inc.
0.58xPrice / tangible book
Market cap
$555.81M
Tangible equity (USD)
$953.63M
Price / tangible book
0.58x
Price / book
0.50x
Net income / ending equity
-5.4%
Net income / ending assets
-5.0%
Efficiency ratio
—
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: FLGT stock price vs SPGI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SPGI's multiple
Needs Annual EPS.
Implied fair value · at FLGT's multiple
Needs FLGT P/E.
Snapshot Sep 8, 2026, 4:00 PM ET
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Multiple discount
Lower is better
Profitability lag
Asset efficiency lag
Lower is better
Statements
Reported bank earnings and balances, with each company’s reporting period shown.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / tangible book
Market cap
$555.81M
Tangible equity (USD)
$953.63M
Price / tangible book
0.58x
Price / book
0.50x
Net income / ending equity
-5.4%
Net income / ending assets
-5.0%
Efficiency ratio
—
Price / book
Market cap
$127.08B
Tangible equity (USD)
-$21.62B
Price / tangible book
—
Price / book
4.08x
Net income / ending equity
14.4%
Net income / ending assets
7.3%
Efficiency ratio
—
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
FULGENT GENETICS, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
S&P Global Inc. · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
NEOGENOMICS INC
FLGT vs NEO
Natera, Inc.
FLGT vs NTRA
Guardant Health, Inc.
FLGT vs GH
EXACT SCIENCES CORP
FLGT vs EXAS
OPKO HEALTH, INC.
FLGT vs OPK
Moody's Corporation
FLGT vs MCO
MSCI Inc.
FLGT vs MSCI
Verisk Analytics, Inc.
FLGT vs VRSK
Intercontinental Exchange, Inc.
FLGT vs ICE
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.